Piramal Pharma Limited share price

Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing; offers inhalation anesthetics, intrathecal therapy for spasticity management, injectable pain management drugs, and other generic and speciality products; and analgesics, skin care, vitamin and mineral supplement, kids' wellness, digestives, and women's health, …Read more

Website NSE हिंदी में BSE

HealthcareDrug Manufacturers - Specialty & GenericNifty 500 Nifty Smallcap 250NSE: PPLPHARMAISIN INE0DK501011

16 Oct 2026, 3:30 PM IST₹197.73▲ 3.30 (1.70%)

Market Cap₹ 26,200 Cr.
Current Price₹ 197.73
High / Low₹ 232 / 132
Stock P/E—
Book Value₹ 62
Dividend Yield0.00 %
ROCE1.2 %
ROE-4.00 %
Face Value₹ 10.0

More figures (10)

EPS (TTM)₹ -2.37
Price / Book3.21
OPM1.8 %
Debt / Equity0.70
Sales growth (3Y)7.8 %
Profit growth (3Y)—
Promoter holding54.5 %
EV / EBITDA34.1
Beta0.34
All-time high₹ 308

Price chart

Price on NSE 50 DMA 200 DMA Volume

Returns	1M	3M	6M	YTD	1Y	3Y CAGR	5Y CAGR
PPLPHARMA	-2.29%	+13.12%	+34.05%	+14.82%	+1.84%	+26.80%	—
Nifty 50	-0.31%	-3.85%	-4.34%	-11.42%	-9.53%	+5.46%	+4.76%

Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.

Quick take

Piramal Pharma Limited is in the Drug Manufacturers - Specialty & Generic industry (Healthcare), with a market value of ₹26,200 crore.
Revenue grew 7.8% a year over the last 3 years.
Return on equity was -4.0% and return on capital employed 1.2% in the latest year.
Debt was 0.70 times shareholders' equity.
The share price is 14.8% below its 52-week high and up 1.8% over one year.
Promoters and insiders hold about 54.5%; institutions about 20.0%.

Pros

No standout strengths in the reported figures.

Cons

Return on equity has been low: -0.9% on average over the last 3 years.
Interest cover is thin: operating earnings are 1.2 times the interest cost.
Institutional (FII + DII) holding has fallen by 13.3 points over 3 years.
The company has not paid a dividend recently.

Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.

AI analysis

Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.

About Piramal Pharma Limited

Employees: 7,120
Head office: Mumbai
NSE industry: Healthcare

HealthcareHealthcareDrug Manufacturers - Specialty & Generic

Part ofNifty 500 Nifty Smallcap 250

S.No.	Company	CMP ₹	P/E	Mar Cap ₹ Cr	Div Yld %	NP Qtr ₹ Cr	Qtr Profit Var %	Sales Qtr ₹ Cr	Qtr Sales Var %	ROCE %	ROE %	P/B	OPM %	Debt / Eq	Prom. Hold. %	Sales ₹ Cr	Sales Var 3Yrs %
1.	Piramal Pharma	197.73	—	26,200	0.00	-69	—	2,270	17.39	1.2	-4.0	3.21	1.8	0.70	54.53	8,869	7.8
2.	Sun Pharmaceutical Industries	1,758.80	34.9	4,21,995	0.91	2,895	34.65	15,184	18.48	17.9	14.7	5.05	23.4	0.06	55.61	58,220	10.4
3.	Divi's Laboratories	9,144.50	83.0	2,42,758	0.33	902	36.25	3,080	19.15	19.0	16.2	14.48	28.4	0.00	52.00	10,476	11.0
4.	Torrent Pharmaceuticals	4,558.90	72.8	1,73,406	0.83	566	3.28	4,921	54.85	9.1	27.1	18.39	25.0	1.79	63.18	13,980	13.3
5.	Zydus Lifesciences	1,123.00	25.0	1,12,020	0.09	940	-19.74	7,802	24.03	19.0	19.7	4.17	21.7	0.46	75.18	26,720	16.5
6.	Laurus Labs	2,060.10	101.8	1,11,310	0.12	362	123.94	2,026	29.10	19.5	18.2	20.98	19.4	0.48	32.03	6,813	3.8
7.	Cipla	1,325.10	31.8	1,07,051	0.98	786	-39.18	7,119	2.33	14.9	11.8	3.11	17.5	0.02	31.13	28,163	7.2
8.	Dr. Reddy's Laboratories	1,233.00	31.0	1,02,707	0.66	444	-68.72	8,071	-5.56	14.2	12.1	2.68	14.9	0.21	30.14	33,593	11.0
9.	Aurobindo Pharma	1,666.90	26.0	95,910	0.00	1,033	14.29	9,106	8.65	13.5	9.9	2.56	15.6	0.21	54.79	33,385	10.7
10.	Mankind Pharma	2,275.50	46.0	93,988	0.00	574	29.12	4,031	12.89	13.7	12.5	5.76	19.9	0.39	75.39	14,278	17.7
	Median: 54 Co.	1,712.85	32.9	14,866	0.27	680	14.29	6,020	17.93	14.6	13.8	4.02	15.7	0.30	54.66	20,499	11.0

Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.

Quarterly Results

Consolidated figures in ₹ crore /

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	1,749	1,911	1,959	2,552	1,951	2,242	2,204	2,754	1,934	2,044	2,140	2,752	2,270
YOY Sales Growth %		11.13%	14.14%	17.97%	11.57%	17.28%	12.54%	7.90%	-0.89%	-8.83%	-2.92%	-0.08%	17.39%
	1,617	1,646	1,690	2,022	1,747	1,900	1,866	2,193	1,827	1,885	1,944	2,291	2,075
Material Cost %	36%	33%	34%	40%	35%	36%	37%	35%	36%	34%	37%	38%	38%
Employee Cost %	28%	27%	27%	19%	30%	25%	25%	22%	32%	30%	28%	21%	30%
Other Expenses %	28%	26%	25%	20%	25%	24%	23%	23%	27%	28%	26%	24%	24%
Operating Profit	132	266	268	530	204	342	338	561	107	159	196	461	195
OPM %	8%	14%	14%	21%	10%	15%	15%	20%	6%	8%	9%	17%	9%
	38	49	62	26	20	61	12	42	58	66	43	46	89
Exceptional items			-32	-31					21		-41	-176
Interest	119	110	106	114	107	108	103	104	86	82	89	83	88
Depreciation	174	185	186	196	185	192	197	243	197	203	213	218	224
Profit before tax	-121	20	5	215	-67	103	50	257	-98	-61	-104	29	-27
		169%	171%	59%		95%	127%	46%				176%
Current tax	25	26	33	101	50	94	72	94	34	55	47	26	65
Deferred tax	-33	8	-24	25	-7	3	-9	25	-32	-2	-5	26	-3
	-99	5	10	101	-89	23	4	154	-82	-99	-136	-9	-69
Profit from associates	14	19	14	12	22	17	17	16	19	15	10	14	20
Profit to shareholders					-89	23	4	154	-82	-99	-136	-9	-69
YOY Profit Growth %				102.10%		350.00%	-63.60%	51.57%		-539.22%	-3,800.82%	-105.75%
EPS in Rs	-0.83	0.04	0.08	0.77	-0.67	0.17	0.03	1.16	-0.62	-0.75	-1.03	-0.07	-0.52
Raw filing

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	846	994	1,024	1,525	1,063	1,284	1,248	1,690	970	1,127	1,196	1,489	1,125
YOY Sales Growth %		19.95%	25.93%	44.64%	25.61%	29.18%	21.89%	10.78%	-8.78%	-12.23%	-4.21%	-11.88%	15.99%
	830	908	899	1,136	912	1,032	1,029	1,273	926	1,000	1,029	1,186	1,008
Material Cost %	49%	50%	48%	46%	42%	42%	43%	43%	44%	41%	45%	44%	44%
Employee Cost %	19%	15%	15%	10%	18%	14%	14%	12%	21%	17%	16%	11%	19%
Other Expenses %	30%	26%	25%	19%	26%	24%	26%	21%	31%	31%	26%	25%	26%
Operating Profit	17	86	126	390	152	253	219	417	44	127	167	303	117
OPM %	2%	9%	12%	26%	14%	20%	18%	25%	5%	11%	14%	20%	10%
	27	89	33	53	37	106	25	40	181	202	96	184	115
Exceptional items											-27	-66
Interest	34	28	17	28	25	30	29	31	23	20	17	20	16
Depreciation	50	51	52	53	52	54	55	61	59	61	65	70	66
Profit before tax	-41	96	90	363	112	276	159	364	143	247	155	332	149
		20%	17%	25%	24%	24%	25%	24%	21%	21%	17%	21%	24%
Current tax		8	18	87	27	62	41	70	20	33	19	43	25
Deferred tax	-8	11	-2	2	-1	4	-0	18	10	19	7	27	11
	-33	77	74	273	85	210	119	277	113	196	129	262	113
YOY Profit Growth %		63.03%		554.87%		172.24%	59.81%	1.53%	32.68%	-6.54%	8.51%	-5.64%	0.30%
EPS in Rs	-0.28	0.61	0.56	2.06	0.64	1.59	0.90	2.09	0.85	1.48	0.97	1.97	0.85
Raw filing

Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Latest quarter on the right.

Profit & Loss

Consolidated figures in ₹ crore /

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	7,082	8,171	9,151	8,869	9,205
YOY Sales Growth %		15.39%	11.99%	-3.08%
	6,453	6,975	7,706	7,947	8,195
Material Cost %	38%	36%	35%	37%	37%
Employee Cost %	27%	25%	25%	27%	27%
Other Expenses %	26%	24%	24%	26%	25%
Operating Profit	628	1,196	1,445	922	1,010
OPM %	9%	15%	16%	10%	11%
	225	175	135	213	244
Exceptional items	-7	-63		-196	-217
Interest	344	448	422	341	343
Depreciation	677	741	816	831	858
Profit before tax	-174	120	342	-233	-163
		135%	95%
Current tax	110	185	310	162
Deferred tax	-44	-24	13	-12
	-186	18	91	-326	-314
Profit from associates	54	59	73	57	58
Profit to shareholders			91	-326	-314
YOY Profit Growth %			411.39%	-457.66%
EPS in Rs	-1.57	0.14	0.69	-2.46	-2.37
Dividend Payout %			16%

Compounded Sales Growth

3 Years:: 8%
TTM:: 1%

Compounded Profit Growth

TTM:: -420%

Stock Price CAGR

3 Years:: 27%
1 Year:: 2%

Return on Equity

4 Years:: -1%
Last Year:: -4%

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	3,443	4,390	5,286	4,782	4,937
YOY Sales Growth %		27.50%	20.40%	-9.53%
	3,346	3,772	4,245	4,140	4,222
Material Cost %	51%	48%	42%	43%	43%
Employee Cost %	16%	14%	14%	16%	15%
Other Expenses %	30%	24%	24%	28%	27%
Operating Profit	98	618	1,040	642	715
OPM %	3%	14%	20%	13%	14%
	341	202	207	663	596
Exceptional items	-7			-93	-93
Interest	116	107	115	80	73
Depreciation	192	205	222	256	262
Profit before tax	124	508	911	877	884
	44%	23%	24%	20%	21%
Current tax	39	112	199	115
Deferred tax	15	4	20	62
	69	391	691	700	700
YOY Profit Growth %		462.91%	76.73%	1.25%
EPS in Rs	0.58	3.05	5.22	5.28	5.27
Dividend Payout %	96%		2%	3%

Compounded Sales Growth

3 Years:: 12%
TTM:: -5%

Compounded Profit Growth

3 Years:: 116%
TTM:: -3%

Stock Price CAGR

3 Years:: 27%
1 Year:: 2%

Return on Equity

4 Years:: -1%
Last Year:: -4%

Financial years ending March; TTM = the last four quarters. Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Dividend payout = dividends paid in the year ÷ net profit.

Balance Sheet

Consolidated figures in ₹ crore, as at 31 March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	1,193	1,323	1,324	1,327
Reserves	5,580	6,588	6,801	6,835
	5,637	4,710	4,856	5,675
Long term borrowings	3,384	2,484	3,214	4,300
Short term borrowings	2,121	2,075	1,506	1,196
	2,112	2,690	2,696	4,128
Trade payables	1,193	1,538	1,534	2,479
Current liabilities	3,843	4,369	3,766	4,758
Total Liabilities	14,523	15,312	15,678	17,965
	4,441	4,816	5,024	5,642
Gross block	6,390	7,180	7,833	9,162
Accumulated depreciation	1,949	2,364	2,809	3,520
Goodwill & intangibles	4,446	4,290	4,087	4,142
CWIP	853	566	489	799
	9,228	9,930	10,165	11,524
Inventories	1,681	2,176	2,313	3,064
Trade receivables	1,799	2,134	2,350	2,158
Cash & equivalents	196	357	369	1,200
Current assets	4,835	5,464	5,797	7,192
Total Assets	14,523	15,312	15,678	17,965

Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.

Cash Flows

Consolidated figures in ₹ crore, financial years ending March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	484	1,005	892	1,653
Profit for the year	-186	18	91	-326
Working capital changes	-302	-234	-488	527
Direct taxes paid	-189	-157	-334	-210
	-1,339	-434	-477	-826
Fixed assets purchased	-965	-712	-664	-890
Fixed assets sold	20	2	5	13
Investments purchased	-1,223	-1,690	-1,885	-992
Investments sold	848	1,949	2,004	997
	818	-422	-441	-39
Proceeds from borrowings	4,385	240	255	903
Repayment of borrowings	-3,186	-861	-1,065	-1,567
Interest paid	-278	-470	-447	-306
Dividends paid	-67		-14	-19
Net Cash Flow	-37	148	-26	788
Free Cash Flow	-481	293	228	763

Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.

Ratios

Ratio	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
ROE	—	-2.8%	0.2%	1.1%	-4.0%
ROCE	—	2.0%	5.7%	7.0%	1.2%
Operating margin	—	-0.7%	5.7%	7.5%	1.8%
Net margin	—	-2.7%	0.2%	1.0%	-3.7%
Debt / equity	—	0.83	0.60	0.60	0.70
Current ratio	—	1.26	1.25	1.54	1.51
Debtor days	—	93	96	95	90
Inventory days	—	205	244	236	312
Days payable	—	145	172	157	253
Cash conversion cycle	—	153	168	174	149
Working capital days	—	52	49	82	101

Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.

Shareholding Pattern

Numbers in percentages · as filed with NSE each quarter

Promoters 34.80%
FIIs 12.52%
DIIs 14.57%
Public 37.63%

%	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	35.02%	35.02%	35.02%	34.95%	34.95%	34.95%	34.95%	34.86%	34.86%	34.86%	34.86%	34.80%
	32.37%	32.51%	30.59%	31.42%	31.73%	31.68%	31.49%	30.86%	30.27%	29.66%	30.18%	12.52%
Foreign portfolio investors (Cat. I)	14.10%	14.26%	12.30%	13.12%	13.32%	13.37%	13.23%	12.67%	12.08%	11.47%	11.98%	12.21%
Foreign portfolio investors (Cat. II)	0.23%	0.21%	0.24%	0.29%	0.41%	0.31%	0.26%	0.24%	0.24%	0.24%	0.24%	0.30%
Foreign direct investment	18.04%	18.04%	18.04%	18.00%	18.00%	18.00%	18.00%	17.95%	17.95%	17.95%	17.95%
	8.02%	9.68%	12.12%	12.95%	13.81%	14.10%	14.78%	14.26%	14.89%	15.69%	15.61%	14.57%
Mutual funds	3.80%	6.28%	9.01%	10.12%	11.21%	11.66%	12.73%	12.32%	13.11%	14.03%	14.12%	13.18%
Insurance companies	3.80%	2.88%	2.64%	2.43%	2.22%	2.13%	1.79%	1.67%	1.49%	1.38%	1.24%	1.02%
Alternative investment funds	0.41%	0.52%	0.47%	0.40%	0.37%	0.30%	0.26%	0.26%	0.29%	0.27%	0.25%	0.36%
	24.21%	22.41%	21.89%	20.21%	19.07%	18.87%	18.44%	19.45%	19.47%	19.35%	19.01%	37.63%
Retail (up to ₹2 lakh)	11.73%	10.59%	10.48%	9.92%	9.50%	9.58%	9.53%	10.48%	10.50%	10.49%	10.44%	11.02%
HNIs (above ₹2 lakh)	5.22%	4.98%	4.65%	4.01%	3.79%	3.71%	3.58%	3.60%	3.61%	3.62%	3.30%	3.52%
NRIs	1.10%	1.10%	1.09%	1.13%	1.08%	1.04%	1.04%	1.03%	1.06%	1.08%	1.10%	1.09%
Bodies corporate	2.15%	1.83%	1.87%	1.48%	1.25%	1.23%	1.20%	1.27%	1.16%	1.30%	1.12%	1.14%
IEPF	0.24%	0.24%	0.24%	0.24%	0.24%	0.24%	0.24%	0.24%	0.24%	0.24%	0.24%	0.24%
No. of Shareholders	3,00,606	2,92,312	2,97,996	3,06,398	3,59,751	4,18,442	4,32,843	4,58,430	4,62,511	4,53,830	4,50,661	4,61,096

Source: shareholding patterns filed by the company with NSE. Public = non-institutional holders. Tap a row marked + for its breakdown.

Mutual funds & institutions holding Piramal Pharma

Holder (above 1%)	Stake
HDFC Flexi Cap FundMutual fund	7.68%

As named in the shareholding pattern for Jun 2026 filed with NSE; mutual funds together hold 13.18% of the company. Shareholders below 1% are not named in the filing.

Documents

Announcements

All announcements on NSE →

Annual reports

Credit ratings

Concalls & investor meets

Filings made by the company with NSE; documents open on NSE's website.

Key dates

Results announced: 4 Nov 2026
Ex-dividend date: 16 Jul 2025
Latest quarter: 30 Jun 2026
Financial year end: 31 Mar 2026

Trade with our broking desk

Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.

Open an account How it works

Latest news

In the news

No recent coverage found.

From the company (NSE)

Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.

Questions about Piramal Pharma Limited

What is the share price of Piramal Pharma Limited today?

Piramal Pharma Limited (PPLPHARMA) last traded at ₹197.73 on NSE (16 Oct 2026, 3:30 PM IST). Prices may be delayed.

What is the market cap of Piramal Pharma Limited?

About ₹26,200 crore at the latest price.

What is the P/E ratio of Piramal Pharma Limited?

The P/E is not available (for example when earnings are negative).

Is Piramal Pharma Limited a good investment?

We do not give views on individual shares. Whether any share suits you depends on your goals, time horizon and risk appetite; for long-term goals, a diversified mutual fund is often a simpler way to own shares. Investments in securities markets are subject to market risks.

How can I buy Piramal Pharma Limited shares?

You need a trading and demat account with a SEBI-registered stock broker. We can help you open one through Parshvanath Investments, an Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539). We provide execution and account service only, not tips or research.

Important. Prices from NSE via Yahoo Finance. Quarterly and annual results, shareholding and documents are taken from the filings the company made with NSE; balance sheet, cash flow and valuation figures are compiled by Yahoo Finance; ratios are computed by us from them. Figures may be delayed or revised. This page is for information only: it is not research, a recommendation or an offer to buy or sell any security. Investments in securities markets are subject to market risks; read all related documents carefully before investing. Plenitude Connect Private Limited is an AMFI-registered Mutual Fund Distributor (ARN-130934); share broking is offered through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539).

Talk to us

Have a question about this topic?

Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.

Get in touch

We typically respond within 2 hours on business days.

Call us

CA Amit Kumar Jain+91 93522 44475 Arihant Jain+91 80056 49698 Poornima Jain+91 92525 44475

Email ussupport@plenitude.co.in

WhatsAppChat with an expert

Visit us5C, Laxmi Colony, Near Bohra Ji Ka Bagh, Opp. Laxmi Mandir Cinema, Tonk Road, Jaipur, Rajasthan 302015

Mon–Sat · 10:00 AM – 7:00 PM IST

In your free consultation

A health check of your current investments
A goal-based plan for retirement, education or a home
Ways to save tax that fit your situation
Clear next steps, with zero pressure to invest

2,000+Investors

₹250 Cr+Client assets

15+ yrsExperience

AMFI Registered Mutual Fund Distributor · ARN-130934

Experts are available Mon–Sat, 10 AM – 7 PM

Book your free wealth consultation

100% free
No obligation
Reply within 2 hours

First name *

Last name *

Email *

Phone *

+91

I'm interested in *

Best day for a call

Preferred time

How can we help? (optional)

Upload your portfolio (optional, get a free expert review)Attach your portfolio statement · PDF, Excel or CSV (e.g. CAS), max 10 MB

I consent to being contacted by Plenitude Connect about financial services. My data will be handled as per the Privacy Policy.

Join 2,000+ investors who plan with Plenitude

Your details are private and never shared.

Piramal Pharma Limited share price

Price chart

Quick take

Pros

Cons

AI analysis

About Piramal Pharma Limited

Peer comparison

Quarterly Results

Profit & Loss

Projection — your assumptions

Related party transactions

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Balance Sheet

Cash Flows

Ratios

Shareholding Pattern

Mutual funds & institutions holding Piramal Pharma

Documents

Announcements

Annual reports

Credit ratings

Concalls & investor meets

Key dates

Trade with our broking desk

Latest news

In the news

From the company (NSE)

Questions about Piramal Pharma Limited

Have a question about this topic?

Book your free wealth consultation

Request received!

What happens next